Improving global access to healthcare has always been a core commitment of our organisation, but we recognise that a challenge of this scale and scope cannot be overcome alone. This is why we are proud to support and co-lead the Access Accelerated initiative.
The initiative is a first-of-its-kind cross-industry collaboration between 24 healthcare and biopharmaceutical companies. We are already working individually to improve the prevention, care and treatment of non-communicable diseases (NCDs) through our medical solutions; however, addressing the barriers to appropriate NCD treatment requires collective action. That’s why we’re working together with partners such as The World Bank Group, the Union for International Cancer Control, international organisations and governments, so that we can address multiple barriers and make measurable and sustainable progress against the rising incidence of NCDs in low- and middle-income countries.
Focusing on non-communicable diseases
We are committed to helping achieve the United Nations Sustainable Development Goals and have targeted the reduction of premature deaths from NCDs.
Historically, the industry and other stakeholders have concentrated their efforts toward infectious diseases, but societal and economic shifts highlight the urgent need to address non-communicable diseases. The main types of NCDs - cancer, cardiovascular diseases, chronic respiratory diseases and diabetes - as well as mental health disorders are the leading causes of death and disability worldwide, accounting for 38 million deaths annually. Nine million people die from NCDs every year before they reach their sixtieth birthday. And most of these premature deaths occur in low and middle-income countries. In these countries, 47% of all NCD deaths occur in those under 60 years old.
Our innovative medicines and diagnostic tests are only meaningful if they reach the people who need them, when they need them – no matter where they live. This is why the Access Accelerated initiative is so important.
Access Accelerated is working towards a future where no one dies prematurely from treatable, preventable diseases, and all people living with or at risk of NCDs have access to appropriate, quality and affordable prevention, treatment and care.
Our work on the ground
Access Accelerated is supporting targeted pilots in selected low- and middle-income countries and cities to understand and overcome multiple challenges, with a view to improving the diagnosis and treatment of NCDs and strengthening health systems. Strong health systems are critical to ensuring sustainability and the ability to achieve the SDG targets. We are also looking at the role of innovative technologies and solutions that will address financing, regulatory and service delivery barriers through partnerships with governments, civil society and health delivery organisations. We need to share best practices, understand the gaps, and find new ways to address them together.
Access Accelerated’s first year in operation has seen us take meaningful steps towards our goal of working in partnership to help address the enormous burden of NCDs in low- and middle-income countries. We invite you to visit the Year One Report, which looks at these key achievements in more detail.
Year One Report
Access Accelerated projects that we are actively engaged with:
The WBG has focused its health sector investments and research in areas that are especially vital to helping countries achieve UHC by 2030, working closely with donors, development partners, governments, and the private sector.
C/Can 2025 is a multi-sectoral initiative supporting cities to take the lead in the design, planning and implementation of cancer treatment solutions to reduce premature deaths from Non-Communicable Diseases (NCD) by 25% by 2025.
The Access Observatory is a reporting mechanism for Access Accelerated, and is also new public reporting platform for programs that aim to improve access to disease prevention and treatment services in low- and middle-income countries.